Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 31st, 2026

LECO_Weekly-Healthcare-News_8-31-2026Download

Healthcare Weekly News and Deals

  1. Sword Health to acquire OrangeDot, the parent company of Headspace, in an all-cash transaction reported between $200-$300 million. Sword Health, last valued at about $4 billion after raising just under $500 million, is buying OrangeDot for cash, with OrangeDot surviving as a wholly owned subsidiary. The $200–300 million range is a severe markdown against the roughly $3 billion at which Headspace and Ginger combined in 2021 and sits below the $321 million Headspace had raised. The deal follows Sword’s $285 million purchase of Kaia Health and extends its move from musculoskeletal care into behavioural health alongside its Mind and Dawn products. The Massachusetts filing dates from 22 July; the effective date is 14 September. (Link)
  2. American Healthcare REIT, Inc. (NYSE: AHR) has completed a $197 million acquisition of two Northern California senior housing communities from a joint venture between Affinius Capital and Alliance Residential Co. American Healthcare REIT has bought Sonrisa Senior Living in Roseville, rebranded Avella at Roseville, and The Watermark at Almaden, 545 units in total, for $197 million. Sonrisa alone traded at $94.1 million. The buyer has now completed roughly $1.4 billion of senior living acquisitions in 2026 and is pursuing a pipeline including $953 million under executed agreements, among them an $873 million Kensington portfolio. Senior housing occupancy reached 89.9% in the second quarter. Note the source headline wrongly casts the REIT as seller. (Link)
  3. Thomas Park Investments has acquired a four-property, $70 million medical outpatient portfolio from Stewart Investment Properties. The Annapolis healthcare real estate platform paid $70 million for 165,637 square feet across three Mid-Atlantic submarkets. The package is 1420 Beverly Road in McLean, a 47,185-square-foot building fully leased and anchored by MedStar Health; 6849 Old Dominion Drive in McLean, 69,330 square feet and 89% leased with Johns Hopkins Medicine as anchor; Children’s National at the former Takoma Theatre on Fourth Street NW in Washington, 24,140 square feet; and Luminis Health Easton Pavilion in Easton, Maryland, 24,982 square feet and fully leased to Luminis Health. Each asset is health-system anchored with remaining term and contractual rent growth. (Link)
  4. Ambulatory Partner Holdings has agreed to pay $54 million for a 60% stake in Atlas Surgery Center, the physician-owned neurosurgical ASC in Amherst, New York. Ambulatory Partner Holdings, an LLC owned equally by Rafael Axen, M.D., Matthew Jenkins and Ann Sariego, is buying 60% from seven of the nine physician members who together hold 90%.. Atlas, at 50 George Karl Boulevard, is a multispecialty Article 28 centre known for outpatient neurosurgery, angiograms, carotid stenting and complex spine, running on the order of 3,000 cases a year. Purchase price is equity-funded. New York’s Public Health and Health Planning Council has the establishment application on its 17 September agenda. (Link)
  5. The Federal Trade Commission has approved the final consent order clearing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The FTC finalised its order on 25 August, letting Ascension close a $3.9 billion purchase first agreed in mid-2025. Six centres go to SC Affiliates, a national ASC operator, and a seventh in Panama City to Florida Gastroenterology Center, a physician group already holding a minority stake. The divestitures cover Nashville, Panama City, Tulsa, Waco and Wichita, where the agency alleged reduced competition in gastroenterology, ophthalmology and orthopaedic outpatient procedures. Ascension must also give the FTC prior notice of ASC acquisitions in those metros for ten years. AmSurg operates more than 250 centres across 34 states. (Link)
  6. McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC from Blackstone (NYSE: BX) for approximately $2.25 billion. McKesson is paying roughly $2.25 billion for the Bethesda-based business after a multi-year Blackstone hold. The buyer is underwriting a services asset rather than a distribution one: biomarker intelligence, laboratory services, a global CRO, market access consulting and commercialisation support. That fits a portfolio McKesson has been reshaping by shedding non-core assets and concentrating capital in oncology and specialty, where Oncology & Multispecialty revenue rose 33% to $14.2 billion in fiscal first quarter 2026. The target will report inside that segment. Closing is subject to customary conditions and regulatory clearances. (Link)
  7. Eli Lilly and Company (NYSE: LLY) to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform aimed at pathogenic autoantibodies. Consideration is cash up to $2.875 billion, covering an undisclosed upfront payment and contingent milestones. Cambridge-based Merida is building biologics that selectively degrade disease-causing antibodies while sparing normal immune function. Lead program MER511 is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing reductions in pathogenic thyroid-stimulating antibodies and a favourable safety profile. A preclinical program, MER769, targets food allergy, asthma and chronic spontaneous urticaria. Merida launched last year with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures. Close is expected in the fourth quarter, subject to customary clearances. (Link)
  8. Argenx SE (Euronext & Nasdaq: ARGX) completed a $2.2 billion all-cash acquisition of Forte Biosciences, Inc. (Nasdaq: FBRX) at $77.00 per share. The close, announced 27 August, follows a cash tender that drew about 87% of Forte shares. The deal adds FB102, which has clinical proof-of-concept in vitiligo and celiac disease and potential application across multiple autoimmune indications, to argenx’s immunology portfolio. The original agreement was signed 27 July at a 40.5% premium to Forte’s then-close. The transaction extends a 2026 pattern of large-cap immunology buyers paying for de-risked, mechanism-differentiated assets rather than waiting for later-stage readouts. Forte is now a wholly owned subsidiary and will delist from Nasdaq. (Link)
  9. Advent International has signed a definitive agreement to acquire a majority stake in New Zealand Clinical Research Group in a transaction local press valued at roughly NZ$1 billion, with Waterman Capital and clinician shareholders rolling over. Advent, one of the largest global private equity firms, is buying majority control of NZCR Group, a physician-led clinical trials platform operating across New Zealand and Australia under the NZCR, CMAX, Optimal and Fusion brands. Advent’s own release did not print a price; BusinessDesk and the Australian Financial Review put the equity value at about NZ$1 billion. Waterman Capital, which held 52%, and clinician shareholders are keeping a significant minority. Close is targeted for the fourth quarter subject to regulatory approvals. Advent will partner with CEO Tony Moffatt to deepen sponsor relationships and extend the network internationally. (Link)
  10. Radiology Partners has signed a definitive agreement to acquire Everlight Radiology from UK private equity firm Livingbridge in a cross-border teleradiology transaction reported at roughly $1 billion (approximately A$1 billion, or about US$715 million). Livingbridge is exiting Everlight after taking majority control in 2021 for a reported US$344 million, having itself bought the asset from Intermediate Capital Group. Everlight’s 800-plus consultant radiologists across 40-plus countries read on a follow-the-sun basis, roughly 2.5 million exams a year for 340-plus clients, avoiding premium US night-shift rates. Radiology Partners intends to extend Mosaic Drafting AI across the acquired network. The 17 August edition covered Livingbridge putting the asset up for sale with Radiology Partners named as bidder; this is the signed agreement. Regulatory clearances pending. (Link)
  11. TowerBrook Capital Partners to acquire a majority stake in Korean-American women’s wellness brand Rael for 400 billion won ($290 million), buying out a shareholder register including SoftBank Ventures, Unilever Ventures, Lotte Shopping, Shinsegae and GS Retail. TowerBrook is paying 400 billion won, about $290 million, for majority control of Rael, according to people familiar with the matter. The sponsor is buying a consumer health asset with a proven digital channel: Rael became Amazon’s top-selling sanitary pad label on an organic feminine care proposition. The cap table it is taking out is unusually broad for a brand of this size, spanning venture investors SoftBank Ventures and Unilever Ventures alongside strategic Korean retail capital from Lotte Shopping, Shinsegae and GS Retail. The deal is a rare cross-border consumer exit for Korean sponsors in a market skewed toward beauty. (Link)
  12. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has filed Chapter 11 and entered a stalking-horse sale with Teva Pharmaceuticals at $57.5 million upfront with milestones up to $125 million. BioXcel and two OnkosXcel subsidiaries petitioned in Delaware on 27 August to run a court-supervised 363 sale of substantially all assets. Teva Pharmaceuticals International GmbH is the stalking-horse bidder for $57.5 million in cash, assumption of specified liabilities, and up to $67.5 million of contingent development payments — a ceiling of $125 million if milestones hit. The estate includes IGALMI, the approved dexmedetomidine sublingual film for agitation, and the pending BXCL501 at-home filing. Teva posted a $5.7 million good-faith deposit and framed the bid as consistent with its Pivot to Growth business-development screen. Higher bids can still emerge at auction. (Link)
  13. Beyond Air, Inc. (Nasdaq: XAIR) has agreed to sell its controlling stake in NeuroNOS Israel Ltd. to Tel Aviv-listed UNIVO Pharmaceutical Industries (TASE: UNVO) for equity, warrants and up to $32.5 million in milestones. Beyond Air is selling 5,000,000 ordinary shares, about 58% of NeuroNOS on a fully diluted basis. Consideration is UNIVO ordinary shares equal to 19.99% of UNIVO’s issued capital, five-year warrants on a further 19.99% of UNIVO awards exercisable at $0.01, plus up to $6.5 million in cash development milestones and up to $26 million in commercial milestones. NeuroNOS is developing blood-brain-barrier-crossing small molecules that regulate nitric oxide, including BA-102 for autism spectrum disorder and Alzheimer’s and BA-101 for glioblastoma, both still preclinical. The sale lets Beyond Air concentrate on its nitric-oxide device franchise. (Link)
  14. Savista, the Alpharetta-based healthcare operations and revenue cycle management company, has acquired ABW Medical, an ambulatory revenue cycle management provider serving federally qualified health centres, medical groups, MSOs and virtual care platforms. Savista is buying its way out of a single-segment concentration. Its existing base is acute: more than 800 clients across 49 states, an Epic-certified training workforce and cancer registry services built over 35 years. ABW Medical adds the non-acute end, including community health centres, FQHCs, rural providers and virtual care, plus preferred RCM partner status inside the athenahealth ecosystem. That diversifies EMR exposure away from Epic dependence and adds safety-net billing around Medicaid wraparound payments. Clients pick up Savista’s global delivery scale and eligibility, coding and A/R tooling. (Link)
  15. Eqwal Group has acquired Atlantic Pro Care, the Portland, Maine prosthetics and orthotics practice, extending the French patient-care network’s East Coast footprint. Eqwal is a global prosthetics and orthotics patient-care group that already owns Steeper in the UK and has been rolling up US clinics including United Prosthetics, American Orthopedics, Optech, South Beach Prosthetics and Prosthetic & Orthotic Group. Atlantic Pro Care, founded in 1993 by J.P. Donovan in Portland, fits custom devices for patients with upper- and lower-limb loss and spinal conditions and handles assessment, fabrication, fitting and rehab. The buyer framed the tuck-in as deepening US patient-care density rather than adding a product brand. No purchase price was published. (Link)
  16. Thurston Group, the Chicago healthcare-focused private equity firm, has made a platform investment in Pixel Health, a Holyoke, Massachusetts provider of IT consulting and managed services to hospitals and large physician groups. Thurston is entering healthcare IT services for the first time through Pixel Health, founded in 2001 and built into a multi-brand group spanning strategy and transformation consulting, managed IT services, and product sales and licensing. Managing partner Dan Davis framed the deal as consistent with the firm’s practice of backing leaders in high-growth healthcare verticals. The sponsor has installed Brad Mondschein, previously the company’s chief operating and legal officer, as chief executive. The investment case is outsourced IT for health systems that cannot staff internally against rising cybersecurity, interoperability and AI-integration complexity. (Link)
  17. BV Investment Partners-backed Imagenet has acquired Analytica Consulting, the California data engineering and artificial intelligence firm, in a transaction that closed on 21 August 2026. Imagenet is moving from transaction-processing BPO toward an end-to-end data and AI solutions position for payers. Analytica Consulting, founded in 2015, brings cloud data warehousing, automated ETL pipelines, enterprise visualisation, data science and governance. The commercial angle is in-situ modernisation: layering pipelines and machine learning models on top of health plans’ existing core systems rather than requiring replacement, and applying prescriptive models to denial trends across digital mailroom, claims adjudication and contact centre lines. The target retains its government, life sciences, manufacturing and education clients. (Link)
  18. Switchboard Health has acquired virtual musculoskeletal provider Livara Health, formerly SpineZone, and closed an oversubscribed equity round of more than $5 million backed by First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. The acquisition converts Switchboard from a referral navigation software layer into a value-based care delivery provider. Livara, founded by orthopaedic spine surgeon Kamshad Raiszadeh, pairs orthopaedic physicians with physical therapists and psychosocial providers, and its outcomes were independently validated by the Validation Institute in 2024 at a 43% reduction in MSK spend, largely through avoided low-value surgery. Switchboard reports routed patient volume up 500% over nine months. This is its second acquisition in under a year after Conduce Health. The raise draws both companies’ existing investors plus new backers. (Link)
  19. WellStack, the Madison, Wisconsin healthcare data platform led by Chief Executive Rich Waller, has acquired DeLorean Artificial Intelligence, the predictive analytics and risk stratification company led by Chief Executive Severence MacLaughlin, to build an end-to-end healthcare decision intelligence platform.WellStack runs an agentic healthcare data platform with a managed data foundation, analytical studio and modular Decision Hubs. DeLorean AI adds continuous evaluation of clinical, claims and operational data to flag emerging risks, predict adverse events and recommend next actions. The combination targets the gap between data aggregation and intervention, moving customers from what happened to what to do about it. Client case studies cite improved patient adherence, reduced avoidable utilisation and revenue optimisation. MacLaughlin framed the merger as necessary for deep integration with health system data lakes and EMRs. (Link)
  20. ALIS, the Chicago-based senior living clinical and operational software platform, has acquired the Ella and elbi technology platforms from TapRoot Interventions & Solutions in its first acquisition. ALIS has grown organically from a clinical EHR into an operating system unifying CRM, clinical, billing, AI and business intelligence; Ella and elbi are its first bought capability. The platforms deliver point-of-care, AI-native guidance to frontline caregivers handling dementia and behavioural episodes, using non-pharmacological, person-centred interventions. The economics sit in two measurable outcomes senior living operators are judged on: fewer high-risk behavioural incidents and reduced psychotropic medication reliance, both increasingly tied to reimbursement and length of stay. The platforms also capture behavioural data for population health reporting. Announced at the buyer’s user conference. (Link)
  21. Globus Medical, Inc. (NYSE: GMED) has acquired Higgs Boson Health, the Durham, North Carolina digital healthcare experience company incubated out of Duke University, to build out its surgical intelligence pillar. What Globus is buying is a team of software developers and AI scientists rather than a revenue base. The acquirer frames the technology as part of a surgical intelligence pillar linking outcomes and analytics in a closed loop across the full episode of care. The stated long-term target is 95% good outcomes at ten years in musculoskeletal surgery, and management is treating patient and provider experience as the missing layer of that ecosystem. The deal follows a second quarter reported on 6 August in which sales grew and non-GAAP EPS guidance was raised. (Link)
  22. Ekoscan Integrity Group, the Eurazeo-backed French non-destructive testing group, has signed a definitive agreement to acquire the US-based NDT Digital business of Carestream Health, Inc., adding the INDUSTREX computed and digital radiography portfolio. Ekoscan is buying Carestream Health’s US NDT Digital unit — computed radiography systems, digital radiography detectors and imaging software under the INDUSTREX brand — plus the commercial, applications and service organisation in Rochester, New York. Radiographic imaging joins the buyer’s existing ultrasound and eddy-current lines, making a multi-method inspection platform for aerospace and defence, oil and gas and power generation. Carestream is narrowing to healthcare imaging. Ekoscan has been an active consolidator, backed by Eurazeo and EDF Pulse Ventures. Closing is expected in the fourth quarter of 2026. (Link)
  23. Golden State Dermatology, the physician-owned platform backed by Sorenson Capital and Yukon Partners, has acquired Summit Dermatology in Colorado Springs, its first move outside California. Golden State Dermatology has been a California story, roughly 45 locations and more than 125 providers built through steady practice tuck-ins with Sorenson Capital and Yukon Partners behind it. Summit Dermatology, led by board-certified dermatologists Kevin Whaley and Jeanne Osborn, is the first out-of-state platform entry and opens the Colorado market. The target offers medical and procedural dermatology including skin cancer screening and Mohs micrographic surgery, and retains its location, phone number and staff. Founder Ed Becker frames the strategy as building the leading comprehensive dermatology network across the Western US. (Link)
  24. Regent Surgical has added Integrated Surgical Center of Arizona, an Avondale multispecialty centre owned by IMS Care, AZ Heart Arrhythmia Associates and Valley GI Consultants, to its ambulatory surgery centre network. Regent Surgical, founded in 2001 and headquartered in Nashville, is a developer and operator of ambulatory surgery centres that has grown from 8 to 32 centres in eight years on site-neutral payment economics. The Arizona addition is a physician-partnership structure rather than an outright buyout: ISCA is owned by IMS Care, the state’s largest independent multispecialty physician group, cardiac electrophysiology group AZ Heart Arrhythmia Associates, and Valley GI Consultants. The strategic value is cardiac migration into outpatient settings across greater Phoenix. Regent also runs a joint venture with Cleveland Clinic. (Link)
  25. Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, the Walnut Creek, California practice founded in 1979 and led by Dr. Gillian Hamilton and Dr. Erica Weiss. Great Point Partners, the Greenwich healthcare-only investor, backed VetnCare in 2022; Geary is the seventh acquisition since, and the second in roughly six weeks after Holistic Veterinary Care in Oakland on 14 July. The company has more than doubled in size in three years under that ownership. The model is regional density rather than national scale: VetnCare concentrates in Northern California, and Geary deepens the East Bay position with a practice offering wellness and preventive care, diagnostics and imaging, surgery, dental and senior pet care. (Link)
  26. Gravity 360, Inc., the Covington, Kentucky parent of Gravity Diagnostics, has acquired Med-Lake Laboratory, LLC, a CLIA-certified, CAP-accredited high-complexity clinical laboratory in Milledgeville, Georgia. Gravity 360 is building a regional laboratory platform across the southern United States, and Med-Lake gives it an operating base outside Kentucky for the first time. Founded in 2018, the target serves physician practices, skilled nursing facilities, behavioural health providers, judicial programmes and urgent care clinics across Georgia and Alabama, with a testing portfolio spanning clinical toxicology, blood and clinical chemistry, PCR infectious disease and reference services. Rather than consolidating volume into Kentucky, the buyer is retaining the Georgia laboratory, its team and its courier network as the foundation for further expansion. (Link)
  27. The Landes Group, the Dallas healthcare real estate investment firm, has completed its acquisition of Encore Medical Center in Bryant, Arkansas from Arkansas Heart Hospital and finalised a long-term lease with the University of Arkansas for Medical Sciences, financed with CGA Capital. The Landes Group has closed on a 108,055 square foot, 53-bed hospital and simultaneously locked in its tenant. UAMS gains capacity without deploying capital, paying annual rent reported at roughly $8.16 million with 2.1% escalation and a purchase option in ten years. That structure is the firm’s core strategy: single-tenant, net-leased healthcare assets where ownership is paired with financing that preserves provider capital. Longstanding financing partner CGA Capital supported the transaction, extending a relationship spanning more than $1.2 billion. Arkansas Heart Hospital operates the facility through 30 September, with UAMS assuming control on 1 October. (Link)
  28. Calera Capital-backed Cypress Health Partners has added Boston Sports Medicine’s ten outpatient clinics to the Bay State Physical Therapy network, effective 27 August. Cypress Health Partners, the Calera Capital-backed outpatient physical therapy platform operating across the Northeast, has partnered with Boston Sports Medicine, one of Greater Boston’s most established physical therapy providers. BSM’s ten outpatient clinics join the Bay State Physical Therapy network, expanding access across Massachusetts communities after more than 25 years of referral-base building. The transaction lands as the outpatient PT sector shifts from pure density plays toward a second phase of value creation focused on patient acquisition and reimbursement yield from existing clinical capacity. (Link)

Venture Deals and Other

  1. RA Capital has joined a $120 million Series C for AusperBio Therapeutics that will fund the Phase 3 registrational program for a functional hepatitis B candidate, taking capital raised since 2024 past $340 million.AusperBio, which operates from Hangzhou and California, closed the $120 million Series C on 31 August led by a new strategic investor, with RA Capital Management joining and existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments returning. Proceeds fund the Phase 3 registrational program and commercialisation work for lead candidate AHB-137, advance next-generation candidate AHB-171, and support combination-therapy development for chronic hepatitis B. The round is the largest venture check in this week’s book and is a China-plus-US therapeutics financing rather than a services deal. (Link)
  2. The Gates Foundation has committed up to $35 million to ProFound Therapeutics, including $20 million initially, to find placental and serum protein targets for preeclampsia and eclampsia. ProFound Therapeutics uses its ProFoundry platform against the expanded human proteome. The Gates money funds discovery of novel proteins expressed in placenta and serum from women with preeclampsia and eclampsia, new drug targets and biomarkers, and a disease-specific AI tool. The initial $20 million is committed now; the balance is contingent on program progress. This is foundation capital rather than a priced venture round, and it sits beside rather than inside the company’s existing equity syndicate. Announced 27 August. (Link)
  3. TJ Parker, general partner at Matrix, has led a $26 million Series A in Metriport, with participation from ARTIS Ventures and Y Combinator, taking the open-source healthcare data infrastructure company to $28.4 million raised. Matrix led the round through TJ Parker, whose stated rationale is channel evidence: he sees dozens of consumer health companies each year and the strongest ones increasingly build on Metriport. The company was founded in 2022 by former AWS engineer Dima Goncharov and Colin Elsinga. The differentiator investors are underwriting is open-source infrastructure against legacy black-box interoperability tools, accessible via a single API, cloud warehouse connection or native EHR application. Customers include Amazon One Medical, Sollis Health and Color Health. Proceeds fund AI chart summarisation and agentic workflows for care teams. (Link)
  4. Define Ventures has led a $25 million Series B in Arintra, with participation from existing investors Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. Define Ventures led the round, taking Arintra’s total funding to $51 million. The investment case rests on measurable throughput: the platform processes more than $5 billion in annual claim value for health systems representing over $50 billion in combined net patient revenue, and reports a 5.1% increase in compliant revenue capture, 32% cost reduction and 43% fewer coding-related denials. Endeavor Health, an early adopter, backed both the Series A and B. Partner Chirag Shah argued no prior solution had been comprehensive enough to move the bottom line. Proceeds fund enterprise expansion and deeper specialty coverage. (Link)
  5. Wing Venture Capital, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures and SV Angel have backed Outer Bio with roughly $23 million as the Cambridge company exits stealth with its Yuna human-skin platform. What the syndicate is funding is a data asset rather than a clinical one: Yuna keeps full-thickness human skin alive and measurable for four weeks against roughly one week for conventional explants, generating longitudinal multi-omic data that improves the machine learning models over time. The commercial route is consumer skincare first, with partnership revenue already flowing. Founded in 2020 by chief executive Michael Polansky, with Stefani Germanotta on the board. The round size and the syndicate signal investors are underwriting a compounding biological dataset rather than a single product launch. (Link)
  6. Saga Ventures has led $22.5 million in seed and Series A funding for Hike Medical, joined by Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc. and angels including Monaco chief executive Sam Blond and Jerod Mayo. Max Altman of Saga Ventures led the financing, and his stated thesis is vertical integration: owning the entire value chain end to end rather than layering software on a broken industry. The market economics justify it, with roughly $100 billion spent annually on orthotics, prosthetics and durable medical equipment and, per the company’s own research, 60 cents of every dollar lost to waste, remakes and fraud. Operating metrics already show remake rates cut from one in 15 to one in 400. Strategic investor and commercial partner Orthofeet participated. Proceeds fund hiring in San Francisco and manufacturing in Peoria, Illinois. (Link)
  7. Costanoa has led a $17 million Series A in Onos Health, joined by Flare Capital Partners and strategic investor CVS Health Ventures, the corporate venture arm of CVS Health Corporation (NYSE: CVS). The strategic money matters commercially: Aetna is already a customer, and the company says it is trusted by three of the six largest US health plans. Costanoa partner Amy Cheetham framed behavioural health as one of the largest and least understood categories in healthcare, with wide cost variation and low correlation to quality. Reported outcomes include a 35% improvement in clinical standard adherence and a 6%-plus cut in behavioural health programme costs within twelve months. Proceeds scale the decision-support tools payers use to manage behavioural benefit design and utilisation. (Link)
  8. Neotribe Ventures, Listen and Village Global have funded a $12 million round for Boston-based Legato, which has emerged from stealth to commercialise AI hearing-assistance glasses. Neotribe founder and managing director Kittu Kolluri framed the investment as a bet against the industry’s design orthodoxy, arguing that decades spent making hearing aids invisible has suppressed adoption and that positioning assistance as a style choice is the route to the market. The defensible asset is intellectual property: four granted patents and more than 20 pending applications. The competitive set is formidable, including EssilorLuxottica’s Nuance Audio and hearing features from Apple and Samsung. Proceeds fund a launch in the coming months and further development. (Link)
  9. August Global Partners has led a $10 million convertible note financing for Shape Memory Medical, joined by fellow new investor Taiwania Capital alongside existing backers HBM Healthcare Investments, Earlybird Venture Capital and WexMed II. The convertible structure defers valuation until clinical readouts land. Partner Davian Sim argued clinicians treating aortic aneurysms and dissections have long relied on repurposed materials, and identified an inflection point as two programmes advance. Proceeds fund follow-up in the AAA-SHAPE pivotal trial, fully enrolled at 180 patients across 48 centres, and the FLAGSHIP feasibility study. Both new investors also support Asia-Pacific expansion. HEAL Venture Lab assisted; the note sits ahead of those readouts rather than pricing the company now. (Link)
  10. Redesign Health has provided $2.25 million in seed funding to OmicsBank, the clinical data infrastructure company founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel.Redesign Health is the sole named backer of this seed round. Head of ventures Neil Patel was explicit about the underwriting order, saying the firm backed the founders first and the market second, citing five companies built between them and the relationship-intensive work of winning hospitals one at a time. The asset being capitalised is a deployed data network: infrastructure inside 90-plus hospitals and laboratories across South Asia, Southeast Asia and the Middle East, covering 12.5 million longitudinal records, 30 million DICOM images, six million pathology slides and 500,000 whole-genome sequences. Proceeds fund US and biopharma expansion. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 3rd, 2026

LECO_Weekly-Healthcare-News_8-3-2026Download
  1. Lawrence, Evans & Co. Closes $30M Cross-Border Refinance and Growth Acquisition Financing for Expanding Healthcare RCM Platform Lawrence, Evans & Co. (LECO) announced the closing of a refinance and growth acquisition financing for a fast-growing healthcare revenue cycle management platform. LECO led the transaction while coordinating multiple acquisitions across several countries and managing the related overseas legal and regulatory requirements. The $30M financing supported the owner’s non-dilutive refinancing and acquisition line of credit needs, letting the company fund growth without giving up equity. Neil Johnson, Managing Partner at Lawrence, Evans & Co., LLC, led the transaction. The deal reflects LECO’s work advising healthcare and technology companies on complex, cross-border capital solutions tied to acquisition strategies. (Link)
  2. Clearview Capital agreed to exit Advantage Behavioral Health in a $610 million municipal-bond-financed sale to nonprofit QCF/I, Inc. Connecticut-based private equity firm Clearview Capital agreed to sell New Jersey-headquartered Advantage Behavioral Health, an operator of mental health centers and sober-living facilities, to nonprofit QCF/I, Inc., which is funding the purchase through a planned $610 million unrated municipal bond issuance. Clearview, together with ABH’s founders and management, is expected to receive roughly $415 million at closing, with up to $100 million more tied to performance milestones. The sale comes just over a year after Clearview recapitalized the company. ABH expects to treat more than 500,000 patients annually and generate about $170 million in revenue and $78 million of EBITDA this year. This is QCF’s fourth and largest acquisition. (Link)
  3. Blue Sea Capital closed an oversubscribed continuation vehicle for One Physics, led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard. Blue Sea Capital, a West Palm Beach private equity firm with over $1.5 billion in assets under management focused on middle-market healthcare companies valued up to $500 million, closed its first continuation vehicle to extend its partnership with One Physics. The meaningfully oversubscribed transaction was led by Apogem Capital, Churchill Asset Management, Dextra Partners and Future Standard, with participation from Abbott Capital and Twin Bridge Capital Partners. Both Blue Sea and One Physics management reinvested significantly. Towson, Maryland-based One Physics is North America’s leading outsourced medical physics provider, with more than 210 physicists delivering regulatory-mandated testing and compliance services to hospitals, imaging centers and cancer facilities. (Link)
  4. Kettering Health signed a non-binding letter of intent for Knox Community Hospital to join its nonprofit system. Knox Community Hospital, a 99-bed nonprofit hospital in Mount Vernon, Ohio, signed a non-binding letter of intent to join Kettering Health, a nonprofit system headquartered in Kettering, Ohio. The two Ohio organizations entered exclusive negotiations toward a definitive agreement by early fall, with closing targeted by the end of 2026 pending regulatory review. As a nonprofit combination, no purchase price applies. Kettering Health committed to significant capital investment in Knox’s service area over the 10 years after closing, including a new EHR system and workforce support. Kettering operates 14 medical centers and more than 100 outpatient locations across western Ohio; Knox would be its farthest medical center beyond southwest Ohio. (Link)
  5. Health Catalyst Capital acquired a leading Midwest provider of psychiatric medical care for elderly and disabled adults to fund regional expansion. New York-based private equity firm Health Catalyst Capital acquired a clinician-led Midwest psychiatric medical care provider serving elderly and disabled adults across long-term care facilities and hospitals. Financial terms were not disclosed, and the target remains unnamed. Both parties are private. Health Catalyst Capital invests in healthcare services and technology businesses and leverages relationships with over 250 healthcare and technology enterprises, driving value by helping portfolio companies integrate AI and build commercial relationships. With the backing, the practice plans to expand its regional footprint into additional long-term care and hospital settings, a segment seeing rising demand as the population ages. (Link)
  6. LiveWell Partners, backed by Encore Management Group, acquired Michigan Community VNA Home Health and Hospice. LiveWell Partners, a St. Louis-based home health and hospice platform backed by private equity firm Encore Management Group, acquired Detroit-based Michigan Community VNA Home Health and Hospice. Financial terms were undisclosed. Founded in 2023, LiveWell has grown largely through Midwest acquisitions and now operates across Illinois, Kansas, Michigan, Missouri and Ohio; this is its third Michigan deal. Under LiveWell’s operating model, acquired organizations keep their community identities and leadership while gaining shared clinical, operational and technology resources. Michigan Community VNA, which traces its roots to 1898, provides skilled home health, therapies, palliative care and hospice across metropolitan Detroit and complements LiveWell’s existing regional density strategy. (Link)
  7. Nexus acquired Telemetrix RPM to extend its clinical care operating system from the hospital to the home. Nexus, formerly Nexus Bedside, acquired Telemetrix RPM, a remote patient monitoring and chronic care management company operating inside native Epic workflows. Financial terms were undisclosed, and both companies are private. The deal, which closed July 23 in Cleveland, unifies inpatient coordination, remote monitoring, chronic care management and cardiac AI into a single workflow. Akram Boutros, MD, serves as CEO of both entities; former Telemetrix CEO Burley Wright becomes COO of Nexus, and founder Bret Shillingstad, MD, stays on as chief medical officer of both. The combination reflects a broader push among health tech providers toward integrated platforms connecting inpatient and post-acute care. (Link)
  8. ARC Health partnered with Old Greenwich, Connecticut-based The Waverly Group to expand collaborative pediatric care. ARC Health, a national network of mental healthcare providers, partnered with The Waverly Group, a multidisciplinary pediatric practice in Old Greenwich, Connecticut. Financial terms were undisclosed, and both organizations are private. Waverly becomes ARC Health’s second Connecticut partner and fourth in the greater New York metro area, offering ABA and behavior therapy, occupational and physical therapy, psychotherapy, psychological testing, speech therapy and related services. The practice keeps its identity and clinical leadership while gaining ARC Health’s operational resources and national provider network. CEO Vince Morra emphasized the coordinated, multidisciplinary model. ARC Health operates a provider-centric structure in which partners become equity-owning members. (Link)
  9. Included Health signed a definitive agreement to acquire Firefly Health to build a clinically integrated health plan alternative for employers. Included Health, an AI-native virtual care and navigation company, agreed to acquire Firefly Health, a clinically integrated health plan and advanced primary care provider serving more than 20,000 members through a network of over 2,300 providers. Financial terms were not disclosed, and the deal is expected to close in the third quarter of 2026 subject to regulatory review. Both companies are privately held. The combination pairs Included Health’s clinician-in-the-loop platform with Firefly’s plan design and near- and in-home network, targeting employers facing steep medical cost trends. Firefly reported 15%+ total cost of care savings and 90% member satisfaction in 2025. (Link)
  10. Graham Partners acquires TechData Service Company to form Quantive Intelligence platform Private equity firm Graham Partners acquired TechData Service Company and combined it with LLX Solutions and R Square Technology to form Quantive Intelligence, a decision-sciences platform focused on biostatistics, statistical programming, and clinical data services. The platform serves pharmaceutical and biotechnology sponsors with submission-stage clinical development support. Headquartered in King of Prussia, Pennsylvania, with operations in Massachusetts, Greater China, and India, the combined organization employs more than 700 people. Financial terms were not disclosed. The transaction closed July 1, 2026. (Link)
  11. Vital Infrastructure Property Trust acquired an EmblemHealth-leased Brooklyn medical office building for approximately $89 million. Toronto-based healthcare infrastructure REIT Vital Infrastructure Property Trust acquired the roughly 140,000-square-foot East New York Health Hub at 101 Pennsylvania Avenue in Brooklyn for about $89 million (C$126.7 million), or more than $635 per square foot, from developer Dominion Management Company. (The linked headline labels the buyer “Global Healthcare REIT,” but the acquirer is Vital Infrastructure Property Trust.) The trophy-quality building is leased long-term to nonprofit insurer EmblemHealth, with additional tenants including AdvantageCare Physicians, New York Cancer & Blood Specialists and Quest Diagnostics. CEO Zach Vaughan called it a step in Vital’s strategy to re-enter the large, fragmented U.S. healthcare real estate market. (Link)
  12. Novanta Inc. (NASD: NOVT) completed its ~$1.2 billion acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta (NASD: NOVT) completed the acquisition of Riverpoint Medical from Washington, D.C.-area private investment firm Arlington Capital Partners, paying approximately $1.2 billion in cash at closing plus a potential $250 million milestone payment due by early January 2027. Riverpoint is a category leader in minimally invasive surgical consumables, including surgical fibers for sports medicine, trauma and cardiovascular applications, with facilities in Portland, Oregon and San Jose, Costa Rica. A Novanta subsidiary borrowed $616 million under its credit facilities, funding the rest with cash on hand and a recent $300 million equity raise. The deal roughly doubles Novanta’s recurring medical consumables revenue to about $300 million. (Link)
  13. Serelora, Inc. acquired the clinical risk-stratification software of ACTIN Care Groups to extend its agentic EHR into population-level analysis. Serelora, a company building an AI-native agentic electronic health record, acquired the clinical risk-stratification software of ACTIN Care Groups. Financial terms were undisclosed, and both companies are privately held. The acquired technology includes WellCheck, a 27-instrument preventive risk battery assessing clinical, behavioral and social risk factors, which becomes a native capability of Serelora’s record. Co-founder and CTO Spencer Wozniak framed the deal as extending the system’s intelligence from the individual chart to whole populations, letting organizations identify who is trending toward risk. The acquisition moves Serelora beyond documentation into population health analytics inside the same agentic system clinicians already use. (Link)
  14. Quasar Medical acquired Medres International’s Nitinol Design and Development Center in San Diego to expand its minimally invasive device manufacturing platform. Quasar Medical, a global contract development and manufacturing organization specializing in minimally invasive devices, acquired the Medres Nitinol Design and Development Center in Carlsbad, California. Financial terms were undisclosed. The transaction covers the 10,000-square-foot facility established in 2024, its engineering talent, manufacturing capabilities and customer relationships. Both parties are private. The site becomes Quasar’s dedicated nitinol center under SVP of Technology Christine Trepanier, complementing hubs in Israel and Galway and sitting an hour from Quasar’s Tecate, Mexico production facility. Medres International retains its remaining business. The deal deepens Quasar’s exposure to nitinol, a widely used enabling material for implantable and disposable devices. (Link)
  15. Transform Health Partners completed an acquisition of Sound Surgeons to expand its platform. Transform Health Partners acquired Sound Surgeons, a bariatric and weight-loss surgery practice, along with Sound Weight & Wellness in Washington state. The deal extends the buyer’s strategy of adding medical facility assets to its portfolio, with a focus on outpatient weight-loss and bariatric services. (Link)
  16. Timshel Health, LLC added Texas-based MyMD Select to its national direct primary care holding company to open new clinics across Texas. MyMD Select, an East Texas direct primary care practice founded in 2014 by Jeremy Smith, MD, joined Timshel Health, a national holding company of direct primary care practices. Financial terms were undisclosed, and both companies are private. MyMD Select guarantees members all-hours access and same- or next-day appointments through functional-medicine-trained providers, and partners with employers to lower spending on labs, imaging and downstream care. With Timshel’s backing, MyMD Select plans to open new clinics throughout Texas. Timshel CEO Mac Findlay framed the deal as helping the practice scale while preserving its culture; Smith becomes MyMD Select’s chief medical officer. (Link)
  17. Private investor acquires Lampert’s Home Therapy A private investor acquired Lampert’s Home Therapy, Inc., a therapist-owned provider of pediatric occupational, physical, and speech therapy services based in Largo, Florida. The company serves children and adults with developmental disabilities across West Central Florida through clinic, home, school, and community settings. Founded in 2000, Lampert’s delivers specialized programs including the TheraSuit Method. Financial terms were not disclosed. The transaction closed June 22, 2026. (Link)
  18. Processa Pharmaceuticals, Inc. (NASD: PCSA) acquired Vidya Therapeutics, Inc. in a stock-for-stock transaction alongside an oversubscribed ~$200 million private placement from a syndicate led by Bain Capital Life Sciences, RA Capital Management and Janus Henderson Investors. Processa (NASD: PCSA) acquired Vidya Therapeutics, adding BTK inhibitor VT-7208, and simultaneously secured approximately $200 million in gross proceeds through Series A preferred stock priced at $1,221.19 per share. The oversubscribed placement drew Bain Capital Life Sciences, Janus Henderson Investors, RA Capital Management, SilverArc Capital, ADAR1 Capital Management, Cormorant Asset Management, Integral Health Asset Management, Marshall Wace, Octagon Capital and Soleus Capital. Proceeds fund operations into the second half of 2029 and three parallel Phase 2 programs. Existing Processa holders are left owning roughly 0.9% on a fully diluted basis, reflecting heavy dilution driven by the incoming investor syndicate. (Link)
  19. Waldencast plc (NASD: WALD) completed the sale of its Obagi Medical dermatological skincare and aesthetics business to mid-market investor Bridgepoint in a transaction valued at up to $460 million. Waldencast (NASD: WALD) closed the divestiture of Obagi Medical to Bridgepoint on July 30, 2026, in a deal valued at up to $460 million. Consideration includes roughly $366 million in cash, $30 million in vendor notes ($10 million fixed, $20 million adjustable) and up to $64 million of earnout tied to 2026 non-injectables and 2027 injectables revenue. Preliminary pro forma total consideration is about $380 million, with net cash proceeds near $334 million. Waldencast used about $178 million at closing to repay its senior term loan, eliminating $135.8 million of long-term debt. The Jersey-incorporated company now focuses on growing Milk Makeup, which generated $110.4 million of 2025 net revenue. (Link)
  20. MiMedx Group, Inc. (NASD: MDXG) agreed to acquire Sanara MedTech Inc. (NASD: SMTI) in a cash-and-stock deal valued at about $350 million. MiMedx (NASD: MDXG) entered a definitive merger agreement to acquire Sanara MedTech (NASD: SMTI) at $35 per share, a total enterprise value of approximately $350 million. Sanara holders receive $33.00 in cash plus 0.4735 MiMedx shares each, a 46% premium to Sanara’s 30-day volume-weighted average price. MiMedx will fund the cash portion with cash on hand and a committed $300 million first lien senior secured term loan from Hayfin Capital Management. The deal combines MiMedx’s surgical portfolio with Sanara’s regenerative surgical technologies, targeting 2027 combined revenue above $400 million, adjusted EBITDA margins over 20% and $20 million-plus in synergies. Closing is expected by year-end, pending Sanara shareholder and regulatory approval. (Link)
  21. Scribe Therapeutics Inc. (NASD: SCTX) closed a $155.5 million IPO at $15.00 per share, with a concurrent private placement to Sanofi. Scribe Therapeutics (NASD: SCTX) completed its IPO, selling 9,867,000 shares at $15.00, including full exercise of the underwriters’ 1,287,000-share option. Aggregate gross proceeds reached about $155.51 million, a figure that includes a concurrent private placement in which strategic partner Sanofi bought 500,000 shares at the IPO price. The shares began trading on the Nasdaq Global Market under ticker SCTX. Scribe is a clinical-stage biotech developing CRISPR-based genetic medicines, with lead candidate STX-1150 targeting PCSK9 to reduce LDL-C. The company, co-founded by Nobel laureate Jennifer Doudna, holds strategic collaborations with Sanofi and Eli Lilly. (Link)
  22. Synlogic and Caldera Therapeutics announce merger agreement and concurrent private placement Synlogic, Inc. (OTC: SYBX) and privately held Caldera Therapeutics entered a definitive all-stock merger agreement. The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker CALD. Concurrently, Caldera secured commitments for an approximately $278 million private placement from a syndicate of healthcare institutional investors. Proceeds are expected to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, with cash runway projected into 2029. (Link)
  23. Thoma Bravo completed its majority-stake acquisition of French occupational health software leader padoa, with existing investors Five Arrows and Kamet Ventures reinvesting. Thoma Bravo, the world’s largest software-focused investment firm with more than $172 billion in assets under management, completed its investment in padoa, the European leader in occupational health, safety and prevention software. The investment was made through Thoma Bravo’s Europe Fund, with significant participation from padoa’s co-founders and existing shareholders Five Arrows (Rothschild & Co’s alternative assets arm) and Kamet Ventures. Thoma Bravo assumes majority control while CEO Cédric Mathorel and the executive team retain a substantial stake. The capital funds AI development, customer service expansion, product innovation and international growth, particularly across the DACH region. padoa had previously raised roughly €105 million pre-buyout. (Link)
  24. PetIQ acquires MYOS muscle health portfolio PetIQ, a leading pet health and wellness company and portfolio company of Bansk Group, acquired MYOS Corp and its Fortetropin-based portfolio of muscle health products for pets. The products support muscle preservation, injury recovery, and healthy aging in companion animals. Terms of the transaction were not disclosed. The acquisition expands PetIQ’s science-backed brand portfolio and strengthens its position in the growing pet health and wellness category. (Link)
  25. Latigo Biotherapeutics files for IPO Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 16 million shares of common stock, with an additional 2.4 million shares available to underwriters. The expected price range is $16.00 to $18.00 per share. Latigo has applied to list on the Nasdaq Global Select Market under the ticker LTGO. Its lead candidates are oral Nav1.8 inhibitors designed to stop pain transmission without addiction risk. (Link)
  26. Attovia Therapeutics files for IPO Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases, filed an amended S-1 registration statement for its initial public offering. The company plans to offer 12.5 million shares of common stock, with an additional 1.875 million shares available to underwriters for overallotments. The expected price range is $15.00 to $17.00 per share. Attovia has applied to list on the Nasdaq Global Market under the ticker ATTO. Proceeds will support clinical development of its ATTOBODY platform candidates. (Link)

Venture Deals and Other

  1. Function secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund to scale its preventive health platform. Function, an Austin-based whole-body health company, closed $450 million in growth financing from General Catalyst’s Customer Value Fund, the firm’s non-dilutive vehicle that ties capital to customer growth rather than equity. General Catalyst manages a portfolio of 800-plus businesses. The financing follows Function’s $298 million Series B in November and its Q2 acquisitions of Getlabs’ nationwide blood-draw network and supplement platform SuppCo. Function offers 160-plus lab tests starting at $365 per year plus MRI and CT scanning across 200-plus locations, and reports 500,000-plus members. (Link)
  2. Healia, an Ohio-based healthcare benefits platform, raised a $14 million Series A led by 111° West Capital with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and Ohio-based North Coast Ventures. Healia, a Columbus, Ohio provider of a healthcare benefits platform for dual-income families and employers, raised $14 million in Series A funding led by 111° West Capital, bringing total funding to $18 million. Participating investors included Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures and North Coast Ventures, a Cleveland, Ohio venture firm. Led by founder and CEO Priyang Shah, Healia builds health reimbursement arrangements that let employers cover employee healthcare costs and premiums when workers enroll in a spouse’s plan. Its platform compares plan options on total cost of ownership, facilitates spousal-plan enrollment and automates claims to reimburse expenses within hours. Proceeds fund operations and product development. (Link)
  3. Flourish Health raised $46 million, with a $26 million Series A led by B Capital, F-Prime and Cherryrock Capital, to scale intensive youth mental health care. Flourish Health, a Richmond, Virginia mental health provider for young people with serious, complex needs, announced $26 million in Series A funding led by B Capital, F-Prime and Cherryrock Capital, which combined with $20 million in previously undisclosed funding brings total capital raised to $46 million. The Series A investors are backing a psychiatrist-led, in-home model delivered through four-person Care Pods and a proprietary AI workflow platform. Studies with major health plans showed 70–96% reductions in hospitalizations and 69–90% reductions in residential treatment. The new capital funds national expansion in partnership with large health plans, platform investment and clinician hiring. (Link)
  4. Doctronic acquired pediatric telehealth company Summer Health, building on its $40 million Series B round backed capital base. Doctronic, an AI-enabled doctor consultation platform, acquired Summer Health, a text-based pediatric telehealth company, to extend primary care to children from birth. Deal terms were undisclosed; both companies are private. Doctronic raised $40 million in Series B funding in March, bringing total funding to $65 million, part of which was earmarked for pediatric expansion. Summer Health, founded in 2022, had raised $11.65 million in Series A funding in 2024 after an earlier $7.5 million round, and has supported more than 100,000 pediatric encounters. Doctronic plans to use Summer Health’s repository of 100,000-plus pediatric conversations to develop pediatric-specific AI models; founder Ellen DaSilva joins to lead B2B growth. (Link)
  5. Epitel, Inc. secured a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand its wireless remote EEG monitoring system. Epitel, a Salt Lake City AI-driven wireless brain health company, closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures, with new and existing investors participating. The capital funds commercial expansion of its REMI Remote EEG Monitoring System, a fully wireless FDA-cleared platform that pairs wearable sensors with AI-driven seizure detection for at-home monitoring over several weeks. The REMI portfolio holds five FDA 510(k) clearances and is cleared for patients as young as one year old. Proceeds scale sales, marketing and customer teams, streamline provider deployment and grow ambulatory market access. Joshua Phillips of Catalyst Health Ventures chairs Epitel’s board. (Link)
  6. Dopl Technologies raised a $6.3 million seed round led by SpringTide Ventures, with participation from WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures and Precursor Ventures. Dopl Technologies, a Bothell, Washington medical technology company developing a robotic ultrasound platform, raised $6.3 million in seed funding led by SpringTide Ventures, bringing total funding above $8 million. WRF Capital, Tacoma Venture Fund, HeartX, Transform Health Ventures, Precursor Ventures and others participated. Led by CEO and co-founder Ryan James, PhD, Dopl combines robotics, AI and remote clinical expertise across its Traverse robotic ultrasound system, Dopl Connect data platform and SonoFlex distributed sonographer workforce tool. The company currently serves critical access hospitals across Washington State. Proceeds fund FDA clearance work, including product verification and validation, submission activities, clinical evaluation and initial market release. (Link)

CLICK HERE to sign up
for all news and updates